Gilead Sciences is pushing full speed ahead with its strategy to ensure global access to its long-acting HIV pre-exposure ...

Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...

Already late with carrying out his administration's prior threats around pharmaceutical tariffs, President Donald Trump has ...

A little over a year after celebrating its 30th anniversary in China with a major production upgrade, Novo Nordisk is back ...

Indian drugmaker Granules has issued a voluntary recall of more than 33,000 bottles of the generic high blood pressure treatment metoprolol succinate, citing the drug's failure to meet dissolution ...

Sanofi and Regeneron, AstraZeneca, Roche’s Genentech and GSK have provided support for the Living Well with COPD educational ...

The idea for Amgen’s first foray into documentary film started with two numbers, according to Nerissa Gomes, general manager ...

The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA ...

As biosimilars struggle to live up to their promise of cutting costs and improving access to biologic medicines for U.S. patients, more than 39 advocacy groups are championing recent bipartisan ...

Southwest Airlines is buckling up to join in on a long-running legal battle surrounding an alleged price-fixing scheme ...

The pharma began its outreach to the HS community well before securing Bimzelx’s approval in the indication. In the spring of ...

Novartis and a Swiss nonprofit have made history, scoring the world’s first approval for a medicine to treat babies who are ...